Search research articles
Contact Us
Filters
Showing results (11-20 of 44) with videos related to
Page
of 5
Sort By:
Current Medicinal Chemistry
|
December 17, 2016
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Spyridon P Basourakos, Likun Li, Ana M Aparicio, et al.
Prostate Cancer
|
December 23, 2011
Epigenetics in prostate cancer
Costantine Albany, Ajjai S Alva, Ana M Aparicio, et al.
Plos One
|
December 11, 2012
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
Shailender Bhatia, James Moon, Kim A Margolin, et al.
European Urology
|
April 17, 2018
Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes
Chad A Reichard, Justin R Gregg, Mary F Achim, et al.
Cancer Research
|
February 24, 2025
Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Yuehui Zhao, Naveen Ramesh, Ping Xu, et al.
Cancers
|
April 3, 2021
Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
Anna S Gerdtsson, Sonia M Setayesh, Paymaneh D Malihi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2011
Modeling a lethal prostate cancer variant with small-cell carcinoma features
Vassiliki Tzelepi, Jiexin Zhang, Jing-Fang Lu, et al.
Journal for Immunotherapy of Cancer
|
October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Investigational New Drugs
|
January 7, 2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879
David I Quinn, Denice D Tsao-Wei, Przemyslaw Twardowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Debashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 44) with videos related to
Sort By:
Page
of 5
Current Medicinal Chemistry
|
December 17, 2016
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Spyridon P Basourakos, Likun Li, Ana M Aparicio, et al.
Prostate Cancer
|
December 23, 2011
Epigenetics in prostate cancer
Costantine Albany, Ajjai S Alva, Ana M Aparicio, et al.
Plos One
|
December 11, 2012
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
Shailender Bhatia, James Moon, Kim A Margolin, et al.
European Urology
|
April 17, 2018
Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes
Chad A Reichard, Justin R Gregg, Mary F Achim, et al.
Cancer Research
|
February 24, 2025
Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Yuehui Zhao, Naveen Ramesh, Ping Xu, et al.
Cancers
|
April 3, 2021
Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
Anna S Gerdtsson, Sonia M Setayesh, Paymaneh D Malihi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2011
Modeling a lethal prostate cancer variant with small-cell carcinoma features
Vassiliki Tzelepi, Jiexin Zhang, Jing-Fang Lu, et al.
Journal for Immunotherapy of Cancer
|
October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Investigational New Drugs
|
January 7, 2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879
David I Quinn, Denice D Tsao-Wei, Przemyslaw Twardowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Debashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Page
of 5